$GMAB News

Genmab A/S Reports Orbis Investment Management Limited Holds 3,166,357 Shares, Representing 5.08% Of Voting Rights As Of May 8, 2026

Genmab Affirms FY2026 Sales Guidance of $4.065B-$4.395B vs $4.300B Est

HC Wainwright & Co. Maintains Buy on Genmab, Lowers Price Target to $38

DARZALEX Worldwide Net Trade Sales Hit $3.964B In Q1, With US Contributing $2.208B Under Genmab's Exclusive License To J&J

Genmab A/S Reports Phase 1/2 RAINFOL-01 Safety Data For Rinatabart Sesutecan Combo In Advanced Ovarian Cancer, Advances Phase 3 Trial In Platinum-Sensitive Patients

Genmab: Multiple Binaries Could Alter The Thesis

Wolfe Research Initiates Coverage On Genmab with Outperform Rating, Announces Price Target of $32

Genmab And Lundbeck Amlenetug Data Adds Nuance To Valuation Debate

Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab

Passing of Genmab A/S’ Annual General Meeting

Genmab A/S Touts Strong 2025, Teases Catalyst-Heavy 2026 With Potential 2027 Launches

Genmab A/S Teases 2026 Wave of Registrational Readouts for EPKINLY, Rina-S and Petosemtamab

Completion of Share Buy-back Program

Transactions in Connection with Share Buy-back Program

Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case

Correction to Company Announcement No. 13 of March 2, 2026

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Wells Fargo Initiates Coverage On Genmab with Overweight Rating, Announces Price Target of $40

Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Weakness

Is Genmab (CPSE:GMAB) Pricing Look Attractive After Recent Share Price Weakness